Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05708235
What this trial is testing

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

Who this might be right for
Breast Cancer
MedSIR 976
Not applicableLooking for participantsNCT06781281
What this trial is testing

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

Who this might be right for
Breast Cancer Invasive
Henan Cancer Hospital 709
Large-scale testing (Phase 3)Study completedNCT02162667
What this trial is testing

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

Who this might be right for
HER2-positive Carcinoma of Breast
Celltrion 562
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06733233
What this trial is testing

A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

Who this might be right for
Breast Cancer, Estrogen Receptor-PositiveHER2 Low Breast Cancer
Guangzhou Women and Children's Medical Center 23
Not applicableLooking for participantsNCT06711068
What this trial is testing

Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy

Who this might be right for
HER2-positive Breast Cancer
Shu Wang 8,077
Early research (Phase 1)Active Not RecruitingNCT05870579
What this trial is testing

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT06001762
What this trial is testing

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Who this might be right for
Breast CancerEarly-stage Breast CancerHigh Risk Breast Carcinoma
Dana-Farber Cancer Institute 90
Not applicableUnknownNCT05870813
What this trial is testing

CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerHormone Receptor Positive Breast Carcinoma
Institut fuer Frauengesundheit 3,000
Large-scale testing (Phase 3)Study completedNCT04109391
What this trial is testing

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

Who this might be right for
HER2-positive Breast CancerEarly-stage Breast CancerBreast Cancer+3 more
Tanvex BioPharma USA, Inc. 338
Large-scale testing (Phase 3)Study completedNCT03588091
What this trial is testing

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 355
Testing effectiveness (Phase 2)Study completedNCT01172223
What this trial is testing

Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
Prof Dirk Elling 81
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07416253
What this trial is testing

Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Henan Cancer Hospital 68
Testing effectiveness (Phase 2)Study completedNCT01401166
What this trial is testing

Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 488
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07136974
What this trial is testing

Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.

Who this might be right for
Breast CancerHER2 + Breast Cancer
Henan Cancer Hospital 280
Testing effectiveness (Phase 2)Ended earlyNCT04113863
What this trial is testing

Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer

Who this might be right for
Breast Neoplasm Female
Mario Negri Institute for Pharmacological Research 76
Testing effectiveness (Phase 2)Study completedNCT00796978
What this trial is testing

Trastuzumab in Treating Older Women With Early-Stage Breast Cancer

Who this might be right for
Breast Cancer
Cynthia Owusu, MD 56
Testing effectiveness (Phase 2)Looking for participantsNCT05704829
What this trial is testing

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

Who this might be right for
HER2-positive Early Breast Cancer
Women's Cancer Study Group GmbH 702
Not applicableStudy completedNCT06363812
What this trial is testing

Probability of OncotypeDx to Reallocate As Low or High Risk of Recurrence Breast Cancer Patients with Uncertain Biology

Who this might be right for
Breast Cancer
Fondazione Sandro Pitigliani 258
Large-scale testing (Phase 3)Looking for participantsNCT07528716
What this trial is testing

Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy

Who this might be right for
Breast Cancer
Fudan University 280
Large-scale testing (Phase 3)Study completedNCT01566721
What this trial is testing

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 2,577
Next Page